MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta ("PI3K") inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16thInternational Conference on Malignant Lymphoma (16-ICML) to be held June 18 – 22, 2021. Details on the two e-poster presentations are included below: Title: Zandelisib, a PI3Kd Inhibitor on Intermittent Schedule (IS) in Follicular Lymphoma Patients who Progressed within 24 Months of First-Line Chemoimmunotherapy (POD24); Authors: John Pagel, et. al.; Abstract ID: 113. Title: COASTAL: A Phase 3 Study of the PI3Kd Inhibitor Zandelisib with Rituximab (R) versus Immunochemotherapy in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (iNHL); Authors: Wojciech Jurczak, et. al.; Abstract ID: 262.